GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Future 3-5Y EPS without NRI Growth Rate

IRLAB Therapeutics AB (OSTO:IRLAB A) Future 3-5Y EPS without NRI Growth Rate : N/A (As of Jul. 14, 2025)


View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, IRLAB Therapeutics AB's Future 3-5Y EPS without NRI Growth Rate is N/A.


Competitive Comparison of IRLAB Therapeutics AB's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, IRLAB Therapeutics AB's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IRLAB Therapeutics AB's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's Future 3-5Y EPS without NRI Growth Rate falls into.


;
;

IRLAB Therapeutics AB  (OSTO:IRLAB A) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.


IRLAB Therapeutics AB Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


IRLAB Therapeutics AB Business Description

Industry
Traded in Other Exchanges
N/A
Address
Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB Headlines

No Headlines